Stocks to Buy

Identifying winning stocks requires more than scanning headlines. InvestorPlace analysts focus on long-term themes, market timing, and structural shifts shaping where capital is flowing next, highlighting stocks positioned to benefit from those trends.

This Pullback is an Opportunity to Buy Atlassian Shares

By Luke Lango, InvestorPlace Senior Investment Analyst
The fundamentals on TEAM stock remain strong. The valuation is tangible. And the technicals look good. So buy the dip.

Why Workhorse Stock Could Rise 300% and Demolish Short Sellers

By Thomas Yeung, CFA, InvestorPlace Markets Analyst
WKHS stock could blow bears out of the water. With Nikola in full retreat, here's why the struggling EV maker could be a "buy"

7 Risky Stocks to Buy Now for Growth and Exciting Returns

By Louis Navellier and the InvestorPlace Research Staff
It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.

3 Big Reasons To Buy the Dip in Adobe Stock

By Luke Lango, InvestorPlace Senior Investment Analyst
ADBE stock is a long-term winner that just fell into undervalued territory. Take advantage of this weakness.

3 Work-From-Home Stocks With More Growth to Come

By Divya Premkumar, InvestorPlace Contributor
As the work environment remains virtual for the foreseeable future, consider investing in these three work-from-home stocks.

Buy This Dip in Alteryx Stock

By InvestorPlace Research Staff
Soft guidance sent AYX stock plunging after earnings last month. But "Big Data" demand means the long-term opportunity remains at the lower valuation.

Another Dip, Another Buying Opportunity For Tesla Stock

By InvestorPlace Research Staff
Tesla stock has pulled back amid disappointment toward Battery Day and valuation concerns. But the long-term story remains attractive.

Inovio Stock Still Has Real Promise Despite Faltering in Vaccine Race

By Faizan Farooque, InvestorPlace Contributor
INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.

Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think

By Thomas Niel, InvestorPlace Contributor
Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.

Here’s How Bed Bath & Beyond Stock Finds Its Way Back up to $20

By Luke Lango, InvestorPlace Senior Investment Analyst
The Bed Bath & Beyond turnaround remains alive and well, so stick with the current rebound rally in BBBY stock.

Upcoming Pixel Event Is Good News for Alphabet Stock

By Louis Navellier and the InvestorPlace Research Staff
Google’s September 30 event will be a bright spot on the calendar for Alphabet stock investors, with the new 5G Pixel 5 set for unveiling.

You Can Bet That DraftKings Stock Will Deliver Portfolio Profits

By Nicolas Chahine, InvestorPlace Contributor
DraftKings stock has shrugged off every dip. The buyers are committed to the trend and it's one to bet on for years to come.

Pinterest Stock May Be Maxed Out At $40

By Luke Lango, InvestorPlace Senior Investment Analyst
PINS stock is a long-term winner that has sprinted into near-term overvalued territory, so it's time to take some profits.

4 Top Stock Trades for Monday: RAD, NCLH, PENN, UNH

By Bret Kenwell, InvestorPlace Contributor
Penn National gaming, UnitedHealth, Rite Aid and Norwegian Cruise Line were our top stock trades for Monday. So, let's look at the charts.

The Power of a ‘Moneyball’ Approach to Stocks

By Louis Navellier, Editor, Growth Investor
Normally reserved for the rich and well-connected, these strategies can help identify the best and worst stock buys in any market.

3 Fallen Tech Stocks to Scoop From the Wreckage

By Luke Lango, InvestorPlace Senior Investment Analyst
These 3 tech stocks to buy look compelling amid the recent tech stock sell-off in early September.

7 Debt-Free Stocks to Buy For Peace of Mind In Volatile Markets

By Bret Kenwell, InvestorPlace Contributor
There are a handful of companies with no debt in the stock market, but not all of them are worth a close look. Here are seven that are.

FDA Clearance Means It’s Go Time for Sorrento Therapeutics

By David Moadel, InvestorPlace Contributor
It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward for Sorrento.

7 Sin Stocks To Buy That Will Outperform the S&P 500

By Tezcan Gecgil, InvestorPlace Contributor
Each of these seven sin stocks has something unique to offer to long-term portfolio, plus juicy dividends and solid fundamentals.
Load More Articles